The new wave of oral weight-loss drugs may work on more than hunger. A study suggests they also quiet the brain circuit behind eating for pleasure — the cravings that push people toward a dessert they don't actually need.
Researchers at the University of Virginia, reporting in Nature, studied orforglipron (a recently approved oral GLP-1 medication) and danuglipron (an experimental one). In mice engineered with human-like GLP-1 receptors, the drugs activated a brain region called the central amygdala and reduced dopamine release in the reward system during pleasure-driven eating.
Hunger vs. craving
Crucially, this appears to be a separate pathway from the appetite-control effect GLP-1 drugs are already known for.
“We've known that GLP-1 drugs suppress feeding behavior driven by energy demand. Now it seems oral small-molecule GLP-1s also dial back eating for pleasure,” said Ali Guler, PhD, of the University of Virginia.
Why it matters
If oral pills can blunt reward-driven eating, that helps explain their power — and points toward drugs that target cravings specifically. But the authors are explicit that this was not a clinical trial: it was done in mice and has not been assessed by the FDA for this effect. Findings in animal brains don't always translate to people. This article is general information, not medical advice.